Related Experiment Video
Updated: Jun 28, 2025
Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy
Published on: April 3, 2018
Identifying Potential SOS1 Inhibitors via Virtual Screening of Multiple Small Molecule Libraries against KRAS-SOS1
Saima Ikram1,2, Ehsan Sayyah1,2, Serdar Durdağı1,2,3
1Computational Biology and Molecular Simulations Laboratory, Department of Biophysics, School of Medicine, Bahçeşehir University, 34734, Istanbul, Turkey.
Abstract:
The RAS-MAPK signaling pathway, crucial for cell proliferation and differentiation, involves key proteins KRAS and SOS1. Mutations in the KRAS and SOS1 genes are implicated in various cancer types, including pancreatic, lung, and juvenile myelomonocytic leukemia. There is considerable interest in identifying inhibitors targeting KRAS and SOS1 to explore potential therapeutic strategies for cancer treatment. In this study, advanced in silico techniques were employed to screen small molecule libraries at this interface, leading to the identification of promising lead compounds as potential SOS1 inhibitors. Comparative analysis of the average binding free energies of these predicted potent compounds with known SOS1 small molecule inhibitors revealed that the identified compounds display similar or even superior predicted binding affinities compared to the known inhibitors. These findings offer valuable insights into the potential of these compounds as candidates for further development as effective anti-cancer agents.
Insights
Researchers identified potential new anti-cancer drugs by screening small molecules targeting the KRAS-MAPK pathway. These compounds show promise as SOS1 inhibitors, offering new therapeutic strategies for various cancers.
Area of Science:
- Molecular Biology
- Biochemistry
- Pharmacology
Background:
- The RAS-MAPK pathway regulates cell growth and differentiation.
- Mutations in KRAS and SOS1 genes are linked to several cancers.
- Targeting KRAS and SOS1 is a key area for cancer therapy research.
Purpose of the Study:
- To identify novel small molecule inhibitors of SOS1.
- To explore potential therapeutic strategies for KRAS- and SOS1-driven cancers.
- To screen small molecule libraries against the KRAS-MAPK interface using in silico methods.
Main Methods:
- Utilized advanced in silico screening techniques.
- Screened small molecule libraries targeting the KRAS-MAPK interface.
- Calculated and compared average binding free energies of identified compounds.
Main Results:
- Identified promising lead compounds as potential SOS1 inhibitors.
- Predicted compounds exhibit comparable or superior binding affinities to known SOS1 inhibitors.
- The identified compounds show potential for anti-cancer drug development.
Conclusions:
- In silico screening successfully identified potential SOS1 inhibitors.
- These compounds represent viable candidates for further development as anti-cancer agents.
- The findings provide valuable insights for developing targeted cancer therapies.
Related Concept Videos
02:04Protein-protein Interfaces
02:38The Ras Gene
Ras is a...